On June 18, WuXi XDC (02268.HK) rose 3.18% in regular trading, trading at HKD 47.14/share, with turnover of HKD 81.26 million. The stock rebounded from recent lows following a key subsidiary development and broad sector strength.

On the news front, WuXi XDC's controlled subsidiary Topharman (01875.HK) signed a process development and manufacturing service agreement with WuXi Biologics on June 16. Under the agreement, Topharman will provide process development and manufacturing services for monoclonal antibody intermediates, delivering a total of 10 batches at RMB 1.9 million per batch, totaling RMB 19 million. The services cover cell recovery, cell passage, N-stage cell culture, protein purification, and excipient addition. All orders must be placed before December 31, with each batch delivered within 60-90 calendar days of order confirmation. The agreement is expected to deepen Topharman's technical know-how and enhance its process capabilities.

Additionally, the broader Life Sciences Tools and Services sector showed strong momentum, with WuXi Biologics up 3.95%, WuXi AppTec up 4.08%, and GenScript Biotech up 4.97%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)